Neuroendocrine and peripheral activities of ghrelin: Implications in metabolism and obesity

European Journal of Pharmacology

Volumn 440, Issue 2-3, 2002, Pages 235-254

  Muccioli, Giampiero ^a   Tschöp, Matthias ^b   Papotti, Mauro ^a   Deghenghi, Romano ^c   Heiman, Mark ^b   Ghigo, Ezio ^d,e  

^a UNIVERSITY OF TURIN   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c Ardana   (France)

^d MOLINETTE HOSPITAL   (Italy)

^e Department of Internal Medicine University of Turin Ospedale Molinette Cso Dogliotti 14 10126 ^*  (Italy)

Author keywords

Food intake, control of; Ghrelin; Growth hormone secretagogue; Metabolic fuel; Obesity; Pituitary hormone

Indexed keywords

APPETITE STIMULANT; EP 80317; GHRELIN; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONIST; GROWTH HORMONE SECRETAGOGUE RECEPTOR ANTAGONIST; IBUTAMOREN; IPAMORELIN; NALOXONE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; PROLACTIN; RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; TRANSCRIPTION FACTOR PIT 1; UNCLASSIFIED DRUG; VASOPRESSIN;

ACYLATION; APPETITE; ARTICLE; EATING DISORDER; GROWTH HORMONE RELEASE; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROENDOCRINE SYSTEM; NONHUMAN; OBESITY; PANCREAS FUNCTION; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN SECRETION; STIMULATION; STOMACH; THEORETICAL STUDY;

ANIMALS; BINDING, COMPETITIVE; CARDIOVASCULAR SYSTEM; CELL DIVISION; DIGESTIVE PHYSIOLOGY; DIGESTIVE SYSTEM; ENERGY METABOLISM; GASTROINTESTINAL MOTILITY; GROWTH HORMONE; HUMANS; NEUROSECRETORY SYSTEMS; OBESITY; PEPTIDE HORMONES; PEPTIDES;

EID: 0037066587     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01432-2     Document Type: Article

References (166)

1. Molecular regulation of eating behavior: New insights and prospects for therapeutic strategies
2. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans
3. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
4. GH secretagogues in aging
5. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: Comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone
6. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin
7. Chronic central infusion of growth hormone secretagogues: Effects on fos expression and peptide gene expression in the rat arcuate nucleus
8. Leptin transport across the blood-brain barrier: Implications for the cause and treatment of obesity
9. Eating disorders
10. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: Minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a
11. Acute cardiovascular and hormonal effect of GH and hexarelin, a synthetic GH-releasing peptide, in humans
12. Cardiac effects of hexarelin in hypopituitary adults
13. Growth hormone secretagogues and hypothalamic networks
14. Identification and chacterization of a new growth hormone-releasing peptide receptor in the heart
15. Growth hormone-releasing peptide (GHRP)
16. GH releasing peptides (GHRPs)
17. Unnatural growth hormone-releasing peptide begets natural ghrelin
18. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans
19. Growth hormone-releasing peptides and their analogs
20. Growth hormone secretagogues: Physiological role and clinical utility
21. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue
22. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines
23. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects
24. Growth hormone secretagogue actions on the pituitary gland: Multiple receptors for multiple ligands?
25. Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs
26. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
27. Human growth hormone and human aging
28. Glucose homeostasis and hypoglicemia
29. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
30. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans
31. Ghrelin acts in the central nervous system to stimulate gastric acid secretion
32. Cardiac ischemia and impairement of vascular endothelium function in hearts from growth hormone-deficient rats: Protection by hexarelin
33. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland
34. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors
35. Motilin-related peptide and ghrelin: Lessons from molecular techniques, peptide chemistry, and receptor biology
36. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6
37. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons
38. Electrical stimulation of the rat periventricular nucleus influences the activity of hypothalamic arcuate neurones
39. GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6
40. Central actions of peptide and non-peptide growth hormone secretagogues in the rat
41. Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6
42. Attenuation of the growth hormone secretagogue induction of Fos protein in the rat arcuate nucleus by central somatostatin action
43. A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control
44. Gastrectomy and osteomalacia: An association not to be forgotten
45. Anatomic basis of leptin action in the hypothalamus
46. Hexarelin protects H9C2 cardiomyocytes from doxorubicin-induced cell death
47. Eating disorders: Obesity, anorexia nervosa and bulimia nervosa
48. Ghrelin and motilin: Two sides of one coin?
49. Fuel partitioning and food intake
50. Leptin and the regulation of body weight
51. Role of hypothalamic neuropeptide Y in feeding and obesity
52. The anti proliferative effect of synthetic peptidyl GH secretagogues in human calu-1 lung carcinoma cells
53. Human aging and the GH-IGF-I axis
54. Orally active growth hormone secretagogues: State of the art and clinical perspectives
55. Growth hormone secretagogues as corticotrophin-releasing factors
56. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects
57. Endocrine and non-endocrine activities of growth hormone secretagogues in humans
58. Biologic activities of growth hormone secretagogues in humans
59. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human
60. Ghrelin, a novel placental-derived hormone
61. Gender and gonadal influences on ghrelin mRNA levels in rat stomach
62. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues
63. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans
64. GH, GH receptor, GH Secretagogue receptor and ghrelin expression in human t cells, b cells and neutrophils
65. Ghrelin in domestic animals: Distribution in stomach and its possible role
66. Bone mineral metabolism after total gastrectomy
67. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats
68. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial
69. An electrophysiological and morphological investigation of the projections of growth hormone-releasing peptide-6-responsive neurons in the rat arcuate nucleus to the median eminence and to the paraventricular nucleus [In Process Citation]
70. Ghrelin and the regulation of energy homeostasis: A hypothalamic perspective
71. Purification and characterization of rat des-Gln14-Ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor
72. Ghrelin and des-acyl ghrelin peptide in gastrointestinal tissue
73. A receptor in pituitary and hypothalamus that functions in growth hormone release
74. Ghrelin: An orexigenic and somatotrophic signal from the stomach
75. Bullfrog ghrelin is modified by n-octanoic acid at its third threonine residue
76. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight
77. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression
78. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats
79. Substantial production of ghrelin by a human medullary thyroid carcinoma cell line
80. Developmentally and regionally regulated expression of growth hormone secretagogue receptor mRNA in rat brain and pituitary gland
81. 9]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: Up-regulation of receptors with atherosclerosis
82. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas
83. Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function
84. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
85. Ghrelin: Discovery of the natural endogenous ligand for the growth hormone secretagogue receptor
86. Immune enhancing effect of a growth hormone secretagogue
87. Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors
88. Presence of ghrelin in normal and adenomatous human pituitary
89. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors
90. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues
91. Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency
92. Effects of growth hormone on bone and muscle
93. Growth hormone-independent cardioprotective effects of hexarelin in the rat
94. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats
95. Activation of arcuate nucleus neurons by systemic administration of leptin and growth hormone-releasing peptide-6 in normal and fasted rats
96. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency
97. Central melanocortins and the regulation of weight during acute and chronic disease
98. Ghrelin stimulates gastric acid secretion and motility in rats
99. Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues
100. Structure-activity relationship of ghrelin: Pharmacological study of ghrelin peptides
101. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors
102. Penile erection induced by EP80661 and other hexarelin peptide analogues: Involvement of paraventricular nitric oxide
103. Neurons with access to the general circulation in the central nervous system of the rat: A retrograde tracing study with fluoro-gold
104. Kidney produces a novel acylated peptide, ghrelin
105. Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland
106. Presence of specific receptors for synthetic growth hormone secretagogues in the human heart
107. Growth hormone-releasing peptides and the cardiovascular system
108. 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland
109. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
110. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women
111. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers
112. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure
113. A role for ghrelin in the central regulation of feeding
114. Intracerebroventricular administration of the growth hormone-releasing peptide KP-102 increases food intake in free-feeding rats
115. Binding sites for growth hormone-releasing peptides
116. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa
117. Life without neuropeptide Y
118. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation
119. Growth hormone secretagogue binding sites in peripheral human tissues
120. Ghrelin-producing endocrine tumors of the stomach and intestine
121. Ghrelin-induced growth hormone secretion in humans
122. Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor
123. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level
124. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
125. Plasma ghrelin concentration and energy balance: Overfeeding and negative energy balance studies in twins
126. Transgenic expression of syndecan-1 uncovers a physiological control of feeding behavior by syndecan-3
127. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
128. Central nervous system control of food intake
129. Ghrelin elicits a marked stimulatory effect on GH secretion in freely-moving rats
130. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway
131. Generation of polyclonal antiserum against the growth hormone secretagogue receptor (GHS-R). Evidence that GHS-R exists in the hypothalamus, pituitary and stomach of rats
132. Peptidomimetic regulation of growth hormone secretion
133. Growth hormone releasing substances: Types and their receptors
134. Adenosine: A partial agonist of the growth hormone secretagogue receptor
135. Growth hormone secretagogue receptor family members and ligands
136. Obesity and the regulation of energy balance
137. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure
138. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats
139. Effects of growth hormone and its secretagogues on bone
140. Ghrelin strongly stimulates growth hormone release in humans
141. Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin
142. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction
143. Identification and characterization of a novel gastric peptide hormone: The motilin-related peptide
144. Novel hexarelin analogs stimulate feeding in the rat through a mechanism not involving growth hormone release
145. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: Indication for multiple growth hormone secretagogue receptor subtypes
146. Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo
147. Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration
148. A review of postgastrectomy bone disease
149. Two important systems in energy homeostasis: Melanocortins and melanin-concentrating hormone
150. Ghrelin induces adiposity in rodents
151. Post-prandial decrease of circulating human ghrelin levels
152. Circulating ghrelin levels are decreased in human obesity
153. Adipogenic effect of a ghrelin receptor antagonist: Lessons from mice lacking neuropeptide Y
154. Adenosine is an agonist of the growth hormone secretagogue receptor
155. Actions of leptin on growth hormone secretagogue-responsive neurones in the rat hypothalamic arcuate nucleus recorded in vitro
156. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans
157. Alterations of circadian rhythmicity and sleep in aging: Endocrine consequences
158. GH inhibition of lipogenesis and stimulation of lipolysis in sheep adipose tissue: Involvement of protein serine phosphorylation and dephosphorylation and phospholipase C
159. Expression of ghrelin and of GHS receptor by pancreatic islet cells and related endocrine tumors
160. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model
161. Effect of CCK pretreatment on the CCK sensitivity of rat polymodal gastric vagal afferent in vitro
162. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat
163. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion
164. Ghrelin causes hyperphagia and obesity in rats
165. Molecular cloning and gene expression of growth hormone-releasing peptide receptor in rat tissues